Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01576666
Title Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals

gastroesophageal junction adenocarcinoma

stomach cancer

colorectal cancer

pancreatic adenocarcinoma

breast cancer


Advanced Solid Tumor


Buparlisib + Sonidegib

Age Groups: adult
Covered Countries USA | CAN

No variant requirements are available.